

IFW



CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

June 8, 2004
Date

Paula S. Linkhart
Signature

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
André DELACOURTE
Nicolas SERGEANT

Serial No.: 10/625,854

Filed: July 23, 2003

For: PREVENTION, TREATMENT AND
DIAGNOSIS OF DISEASES
ASSOCIATED WITH BETA-AMYLOID
FORMATION AND/OR AGGREGATION

Group Art Unit: 1645

Examiner:

Atty. Dkt. No.: 11362.0039.NPUS01

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents B1-B8 and C1-C6 required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner. Copies of the U.S. Patent documents A1-A3 are not enclosed.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any additional fees be required for any reason relating to the enclosed materials, The Commissioner is authorized to deduct said fees from Deposit Account No. 01-2508/11362.0039.NPUS01.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,


Patricia A. Kammerer
Reg. No. 29,775
Attorney for Assignee
Innogenetics N.V.

HOWREY SIMON ARNOLD & WHITE, LLP
750 Bering Drive
Houston, Texas 77057-2198
(713) 787-1400


Date: June 8, 2004

Form PTO-1449 (modified)

List of Patents and Publications for

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
11362.0039.NPUS01Serial No.
10/625,854Applicant
André Delacourte; Nicolas SergeantFiling Date:
July 23, 2003Group:
1645U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Pages 1-3

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	Pub. No. US 2002/0094335	07/18/02	Chalifour et al.			
	A2	4,666,829	05/19/87	Glenner et al.			
	A3	5,876,948	03/02/99	Bruce A. Yankner			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 03/000719	01/03/03	WIPO			
	B2	WO 02/096350	12/05/02	WIPO			
	B3	WO 00/72880	12/07/00	WIPO			
	B4	WO 98/44955	10/15/98	WIPO			
	B5	WO 96/28471	09/19/96	WIPO			
	B6	0 683 234	11/22/95	EPO			
	B7	WO 94/19692	09/01/94	WIPO			
	B8	WO 92/03474	03/05/92	WIPO			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Sergeant et al., "Truncated Beta-Amyloid Peptide Species in Pre-Clinical Alzheimer's Disease as New Targets for the Vaccination Approach," <i>Journal of Neurochemistry</i> , 85:1581-1591 (2003).
	C2	Sigurdsson et al., "Immunization for Alzheimer's Disease," <i>Drug Development Research</i> , 56:135-142 (2002).
	C3	Beka Solomon, "Immunological Concept in the Treatment of Alzheimer's Disease," <i>Drug Development Research</i> , 56:163-167 (2002).

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. 11362.0039.NPUS01	Serial No. 10/625,854
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant André Delacourte; Nicolas Sergeant	
		Filing Date: July 23, 2003	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Pages 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C4	Bruno P. Imbimbo, "β-Amyloid Immunization Approaches for Alzheimer's Disease," <i>Drug Development Research</i> , 56:150-162 (2002).
	C5	Tatsuya Inui, "Synthesis of Amyloid β-Peptides in Solution Employing Chloroform-Phenol Mixed Solvent for Facile Segment Condensation of Sparingly Soluble Protected Peptides," <i>Letters in Peptide Science</i> , 8:319-330 (2002).
	C6	Luigi Bergamaschini et al., "The Region 1-11 of Alzheimer Amyloid-β is Critical for Activation of Contact-Kinin System," <i>Neurobiology of Aging</i> , 22:63-69 (2001).
	C7	Dana Giulian et al., "The HHQK Domain of β-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <i>The Journal of Biological Chemistry</i> , 273(45):29719-29726 (1998).
	C8	V. Meske et al., "The Effects of β/A4-Amyloid and its Fragments on Calcium Homeostasis, Glial Fibrillary Acidic Protein and S100β Staining, Morphology and Survival of Cultured Hippocampal Astrocytes," <i>Neuroscience</i> , 85(4):1551-1660 (1998).
	C9	Michael Y. Aksenov et al., "Oxidative Modification of Glutamine Synthetase by Amyloid Beta Peptide," <i>Free Rad. Res.</i> , 27(3):267-281 (1997).
	C10	Rong Wang et al., "The Profile of Soluble Amyloid β Protein in Cultured Cell Media," <i>The Journal of Biological Chemistry</i> , 271(50):31894-31902 (1996).
	C11	Julia C. Hendrix et al., "A Convergent Synthesis of the Amyloid Protein of Alzheimer's Disease," <i>J. Am. Chem. Soc.</i> , 114:7930-7931 (1992).
	C12	Julia C. Hendrix et al., "Synthesis of a Protected Peptide Corresponding to Residues 1-25 of the β-Amyloid Protein of Alzheimer's Disease," <i>J. Org. Chem.</i> , 57:3421-3426 (1992).
	C13	Julia C. Hendrix et al., "Studies Related to a Convergent Fragment-Coupling Approach to Peptide Synthesis Using the Kaiser Oxime Resin," <i>J. Org. Chem.</i> , 57:3414-3420 (1992).
	C14	Julia C. Hendrix et al., "A Novel Solvent System for Solid-Phase Synthesis for Protected Peptides: The Disaggregation of Resin-Bound Antiparallel β-Sheet," <i>J. Org. Chem.</i> , 55:4517-4518 (1990).
	C15	Peter T. Lansbury, Jr. et al., "A Practical Method for the Preparation of Protected Peptide Fragments Using the Kaiser Oxime Resin," <i>Tetrahedron Letters</i> , 30(37):4915-4918 (1989).

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. 11362.0039.NPUS01	Serial No. 10/625,854
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant André Delacourte; Nicolas Sergeant	
		Filing Date: July 23, 2003	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Pages 1-3</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C16	"Antibodies to Beta Amyloid Proteins", <i>Thalzheimer Research Forum</i> www.alzforum.org On-Line!, 3 June 2002 (retrieved on 2003-10-15).

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)